Heart failure and cardiac hypertrophy

被引：17
作者：
Rame J.E. [1 ]
Dries D.L. [1 ]
机构：
[1] Division of Cardiology, University of California San Francsiso, San Francisco, CA 94143-0124
来源：
Current Treatment Options in Cardiovascular Medicine | 2007年 / 9卷 / 4期
关键词：
Heart Failure; Left Ventricular Hypertrophy; Losartan; Carvedilol; Main Drug Interaction;
D O I：
10.1007/s11936-007-0024-3
中图分类号：
学科分类号：
摘要：
Left ventricular failure is the final common pathway for a wide spectrum of myocardial insults, including systemic hypertension and myocardial infarction. Although left ventricular hypertrophy is an adaptive response to pressure and volume overload, this process becomes maladaptive if left untreated and pathologic cardiac hypertrophy then becomes an important and independent risk factor for the development of heart failure. Despite its importance, the transition from hypertrophy to heart failure in humans is poorly understood. The focus of treatment should be prevention of heart failure and other cardiovascular events, such as stroke and atrial fibrillation. When heart failure is present, treatment with medical and device therapy is then focused on improving functional capacity, increasing survival, and preventing progression to end-stage heart failure. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：289 / 301
页数：12
相关论文
共 26 条
  • [1] Pfeffer J.M., Pfeffer M.A., Mirsky I., Et al., Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat, Proc Natl Acad Sci U S A, 79, pp. 3310-3314, (1982)
  • [2] Litwin S.E., Katz S.E., Weinberg E.O., Et al., Serial echocardiographic Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy, Circulation, 91, pp. 2642-2654, (1995)
  • [3] Molkentin J.D., Lu J.R., Antos C.L., Et al., A calcineurin-dependent transcriptional pathway for cardiac hypertrophy, Cell, 93, pp. 215-228, (1998)
  • [4] Rame J.E., Ramilo M., Spencer N., Et al., Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction, Am J Cardiol, 93, pp. 234-237, (2004)
  • [5] Drazner M.H., Rame J.E., Marino E.K., Et al., Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection within five years. The Cardiovascular Health Study, J Am Coll Cardiol, 43, pp. 2207-2215, (2004)
  • [6] Klapholz M., Maurer M., Lowe A.M., Et al., Hospitalization for Heart Failure in the presence of a normal left ventricular ejection fraction: Results of the New York Heart Failure Registry, J Am Coll Cardiol, 43, pp. 1432-1438, (2004)
  • [7] Vasan R., Larson M.G., Benjamin E.J., Et al., Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort, J Am Coll Cardiol, 33, pp. 1948-1955, (1999)
  • [8] Topol E.J., Traill T.A., Fortuin N.J., Et al., Hypertensive hypertrophic cardiomyopathy of the elderly, N Engl J Med, 312, pp. 277-283, (1985)
  • [9] Levy D., Salomon M., Agostino R.B., Et al., Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy, Circulation, 90, pp. 1786-1793, (1994)
  • [10] Muiesan M.L., Salvett M., Rizzoni D., Et al., Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment, J Hypertens, 13, pp. 1091-1105, (1995)
123